WATCH: Why Netcare has warned shareholders about 2020

Netcare CEO Richard Friedland talks to Business Day TV about the group’s plans

Netcare expects digitisation of patient records to help increase market share

SA's weak economy means and a growth in members covered by restricted hospital networks are expected to weigh on patient day growth

Mediclinic sees no immediate threat from NHI

View is in contrast to the Hospital Association of SA which predicts that the current vision for universal coverage will cause extensive job losses

Mediclinic returns to health as it recovers from Swiss regulatory changes

The group’s operating profit has surged 264% after it wrote down Hirslanden in the prior period

Sizwe Medical Fund restructures risk-transfer contracts

Sizwe has renegotiated fees with service providers from 2020 and drawn up ‘drastically changed’ agreements to stem its losses

WATCH: What Aspen will do to reduce its debt

Aspen CEO Stephen Saad talks to Business Day TV to discuss its plans to sell its Japanese business to a division of Novartis

Aspen on track to meet its debt targets, says CEO Stephen Saad

The sale of its Japanese business to Sandoz is part of the pharma giant's strategy to shed noncore assets and reduce debt

Aspen Pharmacare agrees to sell Japanese unit

Aspen has been disposing of assets to bring down debt, and want to sell its Japanese operations to Sandoz, a division of Switzerland-based Novartis

WATCH: How Dis-Chem set its sights on gaining market share

Dis-Chem CFO Rui Morais talks to Business Day TV about the pharmacy group’s expansion strategy and capital commitments

Four drugmakers withdraw heartburn medicine in SA over safety concerns

A global scare about the active ingredient ranitidine has triggered recalls around the world after being found to contain a carcinogen

Ascendis swings into a loss amid R4.2bn in writedowns

The health group aims to sell off more businesses after suffering impairments totaling more than twice its market capitalisation

Glaxo expects better profit after good sales of shingles vaccine

CEO Emma Walmsley has embarked on a plan to rejuvenate GSK, which has included the spin off or sale of some units since she took over in 2017

Pfizer raises 2019 forecast as new heart drug sales soar

High cost of the largest US drugmaker's popular new heart medicine Vyndaqel, set to be the most expensive ever, faces criticism

Aspen’s share price dips on news of R719m drug writedown

Australian regulators order the recall of heartburn, acid reflux and ulcer medicine Zantac due to possible cancer risks

Life Healthcare takes profit hit from hedging contract

Private hospital group hedged the proceeds from the sale of Indian venture Max Healthcare, which cost it R406m

Eli Lilly’s third-quarter sales miss estimates as rebates crimp profit

The drugmaker is banking on newer drugs to beat competition from cheaper generics

Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.